[Modern fluoroquinolones (ciprofoxacin, levofloxacin) and the treatment of skin and soft tissue infections].
Iakovlev
V P
VP
Svetukhin
A M
AM
Blatun
L A
LA
Ukhin
S A
SA
D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002493:Central Nervous System Diseases / Q000139:chemically induced; D002939:Ciprofloxacin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D064704:Levofloxacin; D008826:Microbial Sensitivity Tests; D015242:Ofloxacin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D012871:Skin Diseases / Q000139:chemically induced; D017192:Skin Diseases, Bacterial / Q000188:drug therapy* / Q000378:metabolism; D018461:Soft Tissue Infections / Q000188:drug therapy* / Q000378:metabolism; D014508:Urea / Q000378:metabolism
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D002939:Ciprofloxacin; D064704:Levofloxacin; D014508:Urea; D015242:Ofloxacin